Clinical trial
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not…
NCT00039962 · SciClone Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00039962 |
|---|---|
| Title | Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin |
| Lead sponsor | SciClone Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a |
| Enrollment | 500 |
| Start date | May 1, 2002 |
| First posted | Jun 19, 2002 |
| Last update posted | Jan 15, 2008 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: